Fennec Pharmaceuticals Inc.
FENC
$6.01
-$0.27-4.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -18.59% | 7.05% | 118.41% | 1,413.24% | 534.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.59% | 7.05% | 118.41% | 1,413.24% | 534.20% |
| Cost of Revenue | -2.34% | 309.97% | 310.81% | 478.95% | 696.51% |
| Gross Profit | -19.82% | -9.17% | 109.44% | 1,469.34% | 524.57% |
| SG&A Expenses | -24.88% | 49.14% | 47.24% | 61.81% | 45.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.32% | 61.66% | 53.94% | 67.47% | 50.63% |
| Operating Income | 48.62% | -411.50% | -7.99% | 360.78% | 70.37% |
| Income Before Tax | 39.60% | -207.18% | -2.00% | 312.11% | 60.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.99% | -207.18% | -2.00% | 312.11% | 60.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.99% | -207.18% | -2.00% | 312.11% | 60.89% |
| EBIT | 48.62% | -411.50% | -7.99% | 360.78% | 70.37% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 27.70% | -198.43% | 1.17% | 308.29% | 60.94% |
| Normalized Basic EPS | 43.61% | -200.23% | 1.17% | 309.53% | 60.53% |
| EPS Diluted | 18.90% | -199.15% | 3.14% | 278.26% | 60.94% |
| Normalized Diluted EPS | 43.61% | -200.23% | 1.17% | 282.29% | 60.53% |
| Average Basic Shares Outstanding | 2.34% | 2.91% | 3.17% | 1.83% | 0.18% |
| Average Diluted Shares Outstanding | 2.34% | 2.91% | 3.17% | 17.06% | 0.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |